Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Pharmaceutical Approaches to Presbyopia Management

By: Milton H. Hom, OD, FAAO; Mile Brujic, OD, FAAO; Ian Benjamin Gaddie, OD, FAAO; Selina McGee, OD, FAAO.

Webinar Credits: 1.5

Emerging pharmaceutical options for the treatment of individuals with presbyopia are poised to enter the eye care landscape. This novel approach represents a completely new paradigm for eye care providers to consider when discussing the array of options available with patients.

Expiration Date: Friday, January 07, 2022
Release Date: January 7, 2021

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Describe the underlying mechanisms of presbyopic changes.
  • Interpret the clinical trial experience published in the literature with pharmaceutical and nonpharmaceutical presbyopia-correcting (PC) options.
  • Differentiate among the pharmacological properties of newly emerging presbyopia correcting drops and their mechanisms of action (MOA).
  • Explain how PC drops are likely to affect categories of patients based on individual characteristics.
  • Compare the side effects of pharmaceutical approaches to presbyopia correction with other treatment options to debate the pros and cons of each strategy.

Accreditation and Designation Statement

Evolve Medical Education LLC (Evolve) is an approved COPE administrator.

This course is COPE approved for 1.5 hours of CE Credit for Optometrists

Sponsored by 

COPE Course #70670-PH

COPE Activity # 120865

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM

Recommended internet speed 5Mbps+

Faculty and Disclosures

FACULTY

Milton H. Hom, OD, FAAO
Program Chair
Private practice
Azusa, California

Mile Brujic, OD, FAAO
Partner, Premier Vision Group
Bowling Green, Ohio

Ian Benjamin Gaddie, OD, FAAO
Owner and Director
Gaddie Eye Centers
Louisville, Kentucky

Selina McGee, OD, FAAO
Founder Precision Vision of Edmond
Edmond, Oklahoma
Adjunct Assistant Professor
Northeastern State University College of Optometry
Tahlequah, Oklahoma


DISCLOSURE POLICY

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:
Mile Brujic, OD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of speaking, writing, participating in an advisory capacity, research or meeting support from: ABB Optical, Akorn, Alcon Laboratories, Allergan, Art Optical, Bausch + Lomb Health, Blephex, Contamac, CooperVision, CSEye, Euclid, Eyevance, Horizon Therapeutics, Johnson & Johnson Vision Care, Luneau, Novartis, Oculus, Optovue, Sight Sciences, Sun Pharma, Tangible Science, TelScreen, TruForm Optics, Valley Contax, Visionary Optics, VMax Vision, Walman Optical, Weave, Carl Zeiss Meditec, and Zea Vision.

Ian Benjamin Gaddie, OD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Aerie, Allergan, Bausch & Lomb, Ivantis, Novarris and Sight Sciences. Grant/Research Support: Aerie. Stock/Shareholder: Tarsus, and Leo Lens.

Milton M. Hom, OD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Grant/Research Support: Allergan, Eyenovia, and Novartis.  Speaker’s Bureau: Allergan.

Selina R. McGee, OD, FAAO, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Cynosure, Dompe, Eyevance, Horizon, Lumenis, Novartis, Optovue, Versant, Vertical. Speaker’s Bureau: Allergan, Lumenis, and Optovue.

The Evolve Medical Education staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Allergan.

Pretest

  • a. 1b. 2c. 3d. 4e. 5

Video Resources

Next

Test

Instructions

Step 1 of 2

  • a. 1b. 2c. 3d. 4e. 5
  • AgreeNeutralDisagree
    Describe the underlying mechanisms of presbyopic changes.
    Interpret the clinical trial experience published in the literature with pharmaceutical and nonpharmaceutical presbyopia-correcting (PC) options.
    Differentiate among the pharmacological properties of newly emerging presbyopia correcting drops and their mechanisms of action (MOA).
    Explain how PC drops are likely to affect categories of patients based on individual characteristics.
    Compare the side effects of pharmaceutical approaches to presbyopia correction with other treatment options to debate the pros and cons of each strategy.
Back